Want to see IT:PHN full AI Analyst Report?
PHN Stock Chart & Stats
€82.50
-€0.20(-0.24%)
At close: 4:00 PM EDT
€82.50
-€0.20(-0.24%)
Day’s Range― - ―
52-Week Range€38.75 - €95.90
Previous CloseN/A
Volume6.65K
Average Volume (3M)11.58K
Market Cap
€747.37M
Enterprise Value€842.83
Total Cash (Recent Filing)€15.14M
Total Debt (Recent Filing)€18.36M
Price to Earnings (P/E)33.6
Beta0.37
Next Earnings
Nov 09, 2026EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend Yield1.64%
Share Statistics
EPS (TTM)2.18
Shares Outstanding9,680,977
10 Day Avg. Volume22,477
30 Day Avg. Volume11,578
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.00Price Target Upside17.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.59
Revenue Forecast (FY)€156.10M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue expansion indicates continued demand for PharmaNutra’s branded nutraceuticals and related formulations. Growth across multiple years supports broader market reach and provides a durable foundation for future earnings, assuming the company can preserve profitability as sales scale.
Strong Cash GenerationPositive operating and free cash flow show that the business is converting a substantial portion of its activity into internally generated funds. This supports reinvestment, working-capital needs, and financial resilience without relying entirely on external financing over the coming quarters.
Improving Leverage And High ROELower leverage and a sizable equity base provide financial flexibility while reducing balance-sheet strain. At the same time, consistently strong return on equity indicates effective capital use, giving PharmaNutra a supportive foundation for sustaining operations and funding growth.
Bears Say
Negative Operating ProfitabilityThe shift from positive to negative operating profitability is a material threat to earnings quality and margin sustainability. If it persists, revenue growth may generate less value, weaken cash conversion, and constrain the company’s ability to reinvest in products, distribution, and partnerships.
Sharp Gross-Margin DeclineA weaker gross margin reduces the contribution available to cover operating expenses and support earnings growth. The pack identifies cost pressure or mix changes as possible explanations; either could remain relevant across several quarters and make future profitability more sensitive to sales composition.
Uneven Cash-Flow DurabilityAlthough current cash generation is positive, its durability is not yet consistent across the reported period. Lower operating-cash-flow coverage of net income suggests working-capital or non-cash effects, while prior negative free cash flow indicates that funding capacity could fluctuate.
PharmaNutra SpA News
PHN FAQ
What was PharmaNutra SpA’s price range in the past 12 months?
PharmaNutra SpA lowest stock price was €38.75 and its highest was €95.90 in the past 12 months.
What is PharmaNutra SpA’s market cap?
PharmaNutra SpA’s market cap is €747.37M.
When is PharmaNutra SpA’s upcoming earnings report date?
PharmaNutra SpA’s upcoming earnings report date is Nov 09, 2026 which is in 51 days.
How were PharmaNutra SpA’s earnings last quarter?
PharmaNutra SpA released its earnings results on Sep 11, 2026. The company reported €0.67 earnings per share for the quarter.
Is PharmaNutra SpA overvalued?
According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued.
Does PharmaNutra SpA pay dividends?
PharmaNutra SpA pays a Annually dividend of €1.2 which represents an annual dividend yield of 1.64%. See more information on PharmaNutra SpA dividends here
What is PharmaNutra SpA’s EPS estimate?
PharmaNutra SpA’s EPS estimate is 0.83.
How many shares outstanding does PharmaNutra SpA have?
PharmaNutra SpA has 9,680,977 shares outstanding.
What happened to PharmaNutra SpA’s price movement after its last earnings report?
PharmaNutra SpA reported an EPS of €0.67 in its last earnings report. Following the earnings report the stock price went down -0.379%.
Which hedge fund is a major shareholder of PharmaNutra SpA?
Currently, no hedge funds are holding shares in IT:PHN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaNutra SpA
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
PHN Stock 12 Month Forecast
Average Price Target
€97.00
▲(17.58% Upside)
Technical Analysis
Garofalo Health Care S.P.A.
―
Arterra Bioscience SpA
―
Eukedos S.p.A.
―
Farmacosmo S.P.A.
―
Svas Biosana S.p.A.
―